WIPO logo
Móvil | Deutsch | English | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Colecciones nacionales e internacionales de patentes
World Intellectual Property Organization
Búsqueda
 
Navegar
 
Traducción
 
Opciones
 
Noticias
 
Conexión
 
Ayuda
 
Resultados 1-10 de 2.541 para loscriterios:(NPCC:GE AND CTR:WO) Oficina(s):all Idioma:ES separación automática de palabras en lexemas: true maximize
Página anterior 1 2 3 4 5 6 7 8 9 10 Página siguiente
Page: / 255  Go >
RSS iconmap icon 
Instant Help

Análisis
Análisis

Extensión de la lista
Pretraducción automatizada
TítuloPaísFecha de publicación
Clasificación InternacionalNº de solicitudSolicitanteInventor/a
1. WO/2016/075513 SUCTIONING DEVICE FOR LARGE ARTIFICIAL WATER BODIESWO19.05.2016
A47L 9/06
PCT/IB2014/065981CRYSTAL LAGOONS (CURACAO) B.V.FISCHMANN TORRES, Fernando Benjamin
The present invention relates to a flexible suctioning device for suctioning floes from the bottom of large artificial water bodies with surfaces larger than 10,000 m and with bottoms covered with plastic liners that do not have centralized filtration systems, and that is able to clean a bottom surface of large artificial water bodies at a surface cleaning rate of 325,000 ft 2 per 24 hours (30,000 m2 per 24 hours) or more, where the bottom surface of the large artificial water bodies can be irregular and sloped, and where the suctioning device is reversible and is supported by a plurality of brushes, comprising first brushes, disposed to provide appropriate support to the suction device and minimize the dispersion and re-suspension of settled floes. The suctioning device is designed in order to concentrate the suction power in a series of suction points, where the suctioning device is connected to an external filtration system that may not be attached to the suctioning device.

2. WO/2016/048188 HIGH AFFINITY AND AGGREGATIVELY STABLE ANTIBODIES ON THE BASIS OF VARIABLE DOMAINS VL AND A DERIVATIVE VHHWO31.03.2016
C07K 16/24
PCT/RU2015/000163CLOSED JOINT STOCK COMPANY "BIOCAD"ULITIN, Andrey Borisovich
What are proposed are: monoclonal antibodies of the type IgG comprising variable domains in the form of a combination of a derivative VHH with a variable domain of a light chain VL. The antibodies mentioned may comprise amino acid substitutions in positions 44 and/or 45 (according to the Kabat numbering scheme) or combinations thereof. The antibodies described have increased affinity and improved aggregation stability.

3. WO/2015/185649 AMINOESTER DERIVATIVESWO10.12.2015
C07D 409/14
PCT/EP2015/062417CHIESI FARMACEUTICI S.P.A.ARMANI, Elisabetta
The invention relates to novel compounds which are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists, methods of preparing such compounds, compositions containing them and therapeutic use thereof. M3 Binging assay: CHO-KI clone cells expressing the human M3- receptor (Swissprot P20309) were harvested in Ca++/Mg++free phosphate-buffered saline and collected by centrifugation at 1500 rpm for 3 min. The pellets were resuspended in ice cold buffer A (15 mM Tris-HCI pH 7.4, 2 mM MgCI2, 0.3 mM EDTA, 1 mM EGTA) and homogenized by a PBI politron (setting 5 for 15 s). The crude membrane fraction was collected by two consecutive centrifugation steps at 40000 g for 20 min at 4°C, separated by a washing step in buffer A. The pellets obtained were finally resuspended in buffer B (75 mM Tris HCI pH 7.4, 12.5mM MgCI2, 0.3 mM EDTA, 1 mM EGTA, 250 mM sucrose), and aliquots were stored at - 80°C. The day of experiment, frozen membranes were resuspended in buffer C (50 mM Tris-HCI pH 7.4, 2.5 mM MgCb, 1 mM EDTA). The non selective muscarinic radio ligand [3H]-N-methyl scopolamine(Mol.Pharmacol.45:899-907) was used to label the M3 binding sites. Binding experiments were performed in duplicate (ten point concentrations curves) in 96 well plates at radioligand concentration of 0.1-0.3 nM. The non specific binding was determined in the presence of cold N-methyl scopolamine 10 uM. Samples (final volume 0.75 mL) were incubated at room temperature for 90 min. The reaction was terminated by rapid filtration through GF/B Unifilter plates and two washes (0.75 mL) with cold buffer C using a Packard Filtermate Harvester. Radioactivity on the filters was measured by a microplate scintillation counter TriCarb 2500 (PerkinElmer). Representative compounds of the invention, when tested in one of the above reported protocols, displayed an IC50 lower than 100 nM. Representative compounds of the invention displayed an IC50 lower than 100 nM in both PDE4 cell free and M3 binding assays.

4. WO/2015/169451 TREATMENT REGIMEN TIACUMICIN COMPOUNDWO12.11.2015
A61K 31/7048
PCT/EP2015/000965ASTELLAS PHARMA EUROPE LTDKARAS, Andreas Johannis
A tiacumicin compound, a stereo-isomer thereof, a polymorph thereof or a pharmaceutically acceptable solvate thereof, and a pharmaceutical composition, containing a tiacumicin compound, a stereo-isomer thereof, a polymorph thereof or a pharmaceutically acceptable solvate thereof, are provided for use in the oral treatment of Clostridium difficile infections (CDI) or Clostridium difficile associated diarrhea or disease (CD AD) in a patient in accordance with a dosage regimen selected from the group consisting of: i. Administering 200 mg of the tiacumicin compound BID for 5 days followed by 5 days of rest and then 200 mg once daily for a further 10 days and ii. Administering 200 mg of the tiacumicin compound BID for 5 days followed by a single 200 mg every other day for 20 days. Further, a method is provided for recovering of gut Bifidobacteria population in a patient, suffering from Clostridium difficile infections (CDI) or Clostridium difficile associated diarrhea or disease (CD AD) and receiving oral treatment with a tiacumicin compound, to 50 to 90 % of the gut Bifidobacteria population prior to administering the tiacumicin compound during days 15-45 after start of the treatment by orally administering the tiacumicin compound to the patient according to a dosage regimen, which is selected from the above-mentioned group.

5. WO/2015/168269 COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7 AGONISTSWO05.11.2015
C07D 487/04
PCT/US2015/028264NOVARTIS AGLI, Yongkai
The invention provides a compounds of formula (I), immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat diseases or disorders associated with Toll-Like Receptor 7 activity.

6. WO/2015/166484 HUMANIZED ANTIBODIES AGAINST CEACAM1WO05.11.2015
C07K 16/28
PCT/IL2015/050433CCAM BIOTHERAPEUTICS LTD.BEN-MOSHE, Tehila
Humanized antibodies, capable of specific binding to human CEACAMl molecules containing human-to-murine back-mutations in non-CDR variable regions, and their encoding polynucleotide sequences are provided. Pharmaceutical compositions comprising these antibodies as well as methods of their use in treating and diagnosing cancer and other conditions are also provided.

7. WO/2015/162205 METHOD AND SYSTEM FOR ANCHORING A WATERPROOFING LINER TO CONCRETE CURBS OF A HYDRAULIC STRUCTUREWO29.10.2015
E02B 3/16
PCT/EP2015/058788CARPI TECH B.V.SCUERO, Alberto, Maria
A method and a system for anchoring a waterproofing liner (13) of thermoplastic material to a longitudinally extending wall (12) of a hydraulic structure (10) of compacted loose material. The waterproofing liner (13) is seamed to a plurality of continuous anchor bands (14) of thermoplastic material, laterally spaced apart from one another, vertically extending in a traverse direction of the wall (12), from an upper to a lower position of the hydraulic structure (10); each continuous anchor band (14) consists of a plurality of axially aligned and partially superimposed modular strips (14''), seamed together and fixed to concrete curbs (15), defining a surface for laying down the waterproofing liner (13), in which the curbs (15) longitudinally and/or transversely extend to the wall (12) of the hydraulic structure (10).

8. WO/2015/162515 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDSWO29.10.2015
A61K 31/4355
PCT/IB2015/052594PFIZER INC.GRAY, David Lawrence Firman
The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1 -associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, Parkinson's disease, anxiety, and depression.

9. WO/2015/162516 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDSWO29.10.2015
C07D 471/04
PCT/IB2015/052604PFIZER INC.GRAY, David Lawrence Firman
The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1 -associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, Parkinson's disease, anxiety, and depression.

10. WO/2015/163485 ISOINDOLINE-1-ONE DERIVATIVES AS CHOLINERGIC MUSCARINIC M1 RECEPTOR POSITIVE ALLOESTERIC MODULATOR ACTIVITY FOR THE TREATMENT OF ALZHEIMERS DISEASEWO29.10.2015
C07D 209/46
PCT/JP2015/062912TAKEDA PHARMACEUTICAL COMPANY LIMITEDYAMADA, Masami
The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. (I) wherein each symbol is as described in the specification, or a salt thereof.


Resultados 1-10 de 2.541 para loscriterios:(NPCC:GE AND CTR:WO) Oficina(s):all Idioma:ES separación automática de palabras en lexemas: true
Página anterior 1 2 3 4 5 6 7 8 9 10 Página siguiente
RSS iconmap icon 
Instant Help